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Abstract 
This study investigates predictors of outcome in a secondary analysis of dropout and 
completer data from a randomized controlled effectiveness trial comparing CBTp to a wait-
list group (Lincoln et al., 2012). Eighty patients with DSM-IV psychotic disorders seeking 
outpatient treatment were included. Predictors were assessed at baseline. Symptom outcome 
was assessed at post-treatment and at one-year follow-up. The predictor x group interactions 
indicate that a longer duration of disorder predicted less improvement in negative symptoms 
in the CBTp but not in the wait-list group whereas jumping-to-conclusions was associated 
with poorer outcome only in the wait-list group. There were no CBTp specific predictors of 
improvement in positive symptoms. However, in the combined sample (immediate CBTp + 
the delayed CBTp group) baseline variables predicted significant amounts of positive and 
negative symptom variance at post-therapy and one-year follow-up after controlling for pre-
treatment symptoms. Lack of insight and low social functioning were the main predictors of 
drop-out, contributing to a prediction accuracy of 87%. The findings indicate that higher 
baseline symptom severity, poorer functioning, neurocognitive deficits, reasoning biases and 
comorbidity pose no barrier to improvement during CBTp. However, in line with previous 
predictor-research, the findings imply that patients need to receive treatment earlier. 
Keywords: predictors, schizophrenia, psychosis, CBT, dropout, adherence 
1. Introduction 
Cognitive behavioural therapy for psychosis (CBTp) has been demonstrated to be 
effective for psychotic disorders (Wykes et al., 2008) and has been incorporated into several 
national guidelines (Gaebel et al., 2009; NICE, 2009). Nevertheless, a number of patients 
discontinue therapy (on average 16% according to a meta-analysis by Lincoln et al., 2008) 
and among those that continue, approximately half do not show reliable symptom 
improvement (Jones et al., 2004; Wykes et al., 2008). Knowing who is likely to benefit from 
CBTp would provide a better basis for an evidence-based allocation of patients to treatment. 
Furthermore, knowing about who is unlikely to benefit helps us to understand where CBTp 
needs to be adapted in order to serve specific groups more effectively.  
Several studies have attempted to identify baseline predictors of improvement in 
CBTp. In regard to socio-demographic variables, these studies have found that younger 
patients benefit more in terms of positive symptoms (Thomas et al., 2011; Morrison et al., 
2012) and that women benefit more than men in overall psychopathology (Drury et al., 1996; 
Brabban et al., 2009). Furthermore, higher level of education was shown to predict better 
outcome in negative symptoms (Allott et al., 2011).  
A clinical baseline variable relevant to outcome is a shorter duration of treated or 
untreated psychosis, which has been found to be associated with a shorter recovery time 
(Drury et al., 1996), greater symptom improvement during CBTp (Tarrier et al., 1998; 
Thomas et al., 2011; Morrison et al., 2012), and less symptomatology at post-assessment 
(Morrison et al., 2004). Also, lower baseline symptomatology overall was shown to be related 
to more symptomatic improvement during CBTp (Tarrier et al., 1998), in particular less 
pronounced negative symptoms were related to greater symptom improvement (Thomas et al., 
2011) and outcome (Allott et al., 2011). In contrast, there is some indication that more severe 
positive symptoms were a positive predictor of symptom improvement (Morrison et al., 2004; 
Dunn et al., 2006). No study found baseline depression to be related to outcome.  
Higher insight into the disorder predicted overall symptom improvement in two 
studies (Garety et al., 1997; Naem et al., 2008). Interestingly, Garety et al. (1997) also found 
that among patients with delusions acknowledging the possibility of being mistaken was a 
predictor of better outcome, although this was strongly associated with insight. Similarly, 
Brabban et al. (2009) found lower delusion conviction to be associated with overall symptom 
reduction in a subgroup of patients with delusions who had received CBTp. On a similar note, 
cognitive insight, in terms of self-reflectiveness and self-certainty was found to be predictive 
of favorable outcome (Perivoliotis et al., 2010; Premkumar et al., 2011).  
Furthermore, higher baseline occupational functioning predicted lower levels of 
positive symptoms at one year (Allott et al., 2011). With regard to neurocognitive variables, 
Penades et al. (2010) found better baseline memory performance to predict symptom 
improvement following treatment. However, most studies (Garety et al., 1997; DeVille et al., 
2011; Premkumar et al., 2011) failed to find predictive value of memory, executive 
functioning, attention, or verbal fluency on outcome of CBTp.  
One problem in drawing valid conclusions from the previous research is that studies 
have focused on different domains and time-points of outcome. Moreover, most studies are 
inconsistent in whether they investigate unspecific predictors of change or those specific to 
CBTp or even merely predict symptom levels at post-therapy without controlling for baseline 
symptoms. Nevertheless, previous findings highlight the positive predictive value of a shorter 
duration of psychosis and better insight on outcome. They also indicate that more pronounced 
negative symptoms at baseline is associated with less favorable outcome, whereas more 
severe baseline positive symptoms seems to be positively related to symptom improvement. 
The majority of studies do not find neurocognitive functioning to be a predictor of outcome, 
while there are singular findings indicating that patients with higher education, younger age, 
and female gender might benefit more from CBTp.  
Surprisingly, some predictors that are likely to be specifically relevant to CBTp have 
not received sufficient attention. Psychotic symptomatology is associated with a range of 
reasoning biases, such as jumping-to-conclusions, difficulties in theory of mind and 
attribution biases and, consequently, CBTp has a strong focus on increasing peoples’ ability 
to question their beliefs and to take more time to weigh the evidence before drawing 
conclusions (Kuipers et al., 2006). This also involves learning to take peoples’ cognitive and 
emotional perspective. On a transdiagnostic level, there is some indication that people with 
stronger cognitive resources (in the sense of fewer dysfunctional attitudes) benefit more from 
cognitive approaches (e.g. Sotsky et al., 1991). Garety et al.’s (1997) finding that less 
pronounced delusion-conviction and cognitive flexibility were associated with better outcome 
seems to support this for psychosis. It would therefore be interesting to test whether lower 
levels of reasoning biases predict better outcome. Second, psychosis generally goes along 
with a range of comorbid disorders, in particular anxiety disorders and depression (Fenton, 
2001). In clinical practice, CBTp also targets these disorders. Due to the high efficacy of 
cognitive behavioral interventions for anxiety disorders and depression (Butler et al., 2006), 
patients with comorbid Axis I disorders might benefit more from therapy than those for whom 
the sole focus lies on psychotic symptoms. In contrast, Axis II disorders are likely to 
complicate and prolong therapy and have been found to a negative predictor of outcome in 
treatment of depression and anxiety (Reich, 2003).   
With regard to outcome, most of the studies have focused on global symptomatology, 
positive symptoms (as the prime target of CBTp) or functioning. To our knowledge, no study 
has attempted to predict improvement in negative symptoms although it is agreed that 
negative symptoms constitute a distinct and important therapeutic domain (Kirkpatrick et al., 
2006). Finally, although predictors of dropout related to psychosocial treatments for 
schizophrenia in general have been investigated – finding age, gender, duration of disorder 
and treatment-related variables to be associated with dropout (Villeneuve et al., 2010), only 
one study, by Periviolitis et al. (2010), has focused specifically on drop-out during CBTp. 
The aim of this study is therefore to extend the research on baseline predictors of 
short- and long-term improvement in positive and negative symptoms and dropout in a large 
and clinically heterogeneous sample of patients who received CBTp. The study is a secondary 
analysis of dropout and completer data from a randomized controlled effectiveness trial of 
CBTp for psychosis (Lincoln et al., 2012) that found significant improvement in positive 
symptoms and overall psychopathology but not in negative symptoms in the CBTp compared 
to a waitlist group. Over and above the predictors investigated in previous studies, we will 
analyze the impact of social cognition and reasoning which we expect to have unique 
relevance to CBTp, as well as the impact of comorbidity.  
 
2. Method 
2.1.Design 
The study was a single-center stratified (based on the PANSS total scores), single-
blind, wait-list controlled, parallel group study comparing a CBTp group (n=40) to a wait-list 
(WL) group (n=40) with regard to psychopathology at the end of treatment. As illustrated in 
Figure 1, the WL group received CBTp after the waiting-period. All patients were re-assessed 
at a one-year-follow-up. Therefore this design allowed for controlled comparisons at post-
therapy, but was limited to pre-post comparisons for the one-year follow-up (Lincoln et al., 
2012).  
In the CBTp group all predictors were assessed at baseline, prior to treatment (t1), and 
outcome variables (positive and negative symptoms) were assessed at post-treatment (t2) and 
at one-year follow-up (t4). In the WL group, predictors were assessed at t1, outcome was 
assessed at post-waiting time (t2). Furthermore, the predictors that were assumed to be more 
sensitive to change (depression, delusion conviction, insight, functioning, and reasoning 
biases) were reassessed for this group at t2. Finally, this group was reassessed on the outcome 
variables after having received treatment (t3) and at one-year follow-up (t4). 
Of the 40 patients randomized to the CBTp group, 34 completed therapy. In the WL 
group, 39 patients completed the assessments after the waiting-period and 33 completed 
therapy thereafter. A detailed trial flow is depicted in Lincoln et al (2012).  
In this study we investigated 1) differential predictors of CBT versus WL by analyzing 
the predictive value of variables assessed at baseline (t1) on symptom outcome in participants 
who had completed CBTp (CBTp group: n=34) or treatment-as-usual (WL group: n=39); 2) 
the predictors of change during therapy by combining all treatment completers in the 
immediate (n=34) and the delayed (n=34) therapy group and investigating the predictive value 
of pre-therapy variables assessed at t1 (immediate therapy group) and t1/t2 (delayed therapy 
group) on outcome at t3 and t4; 3) the predictors of dropout by comparing patients who 
completed CBTp (n=68) or dropped out after the initial rapport and assessment phase during 
the waiting period  (n=1) or therapy (n=11).  
The individualized CBTp was delivered according to a published German-language 
manual (Lincoln, 2006) and involved assessment, establishment of working alliance and case-
formulation, working with auditory hallucinations and other distressing or disabling 
symptoms, modifying delusional and other dysfunctional beliefs and relapse prevention. The 
interventions did not follow a specific order or involve a fixed number of sessions.  
2.2.Assessments of outcome and predictor variables 
Positive and negative symptoms were assessed with the Positive and Negative Syndrome 
Scale (PANSS; Kay et al., 1987). The PANSS is a semi-structured interview measuring 32 
symptoms divided into three groups: positive symptoms (e. g. persecutory delusions, thought 
disorder, grandiosity), negative symptoms (e. g. blunted affect, emotional withdrawal, poor 
rapport), and general psychopathology (e. g. anxiety, tension, lack of insight). Symptoms are 
rated using a seven-point-scale on the basis of detailed descriptions and a semi-structured 
interview (SCI-PANSS). The interviews were videotaped and rated by independent and 
treatment-blind raters who were trained and certified by the PANSS Institute (see 
http://www.panss.org/).  
Socio-demographic and clinical characteristics (duration of disorder, previous 
hospitalizations, comorbidity), neurocognitive performance, cognitive biases and social skills 
were assessed at baseline. Baseline was directly prior to therapy for the CBTp group (t1) and 
four months prior to therapy for the WL group (t2). Baseline-symptoms, functioning and 
cognitive biases were assessed directly prior to therapy for all patients.  
Clinical variables. Comorbid diagnoses were assessed with the Structured Clinical 
Interview for DSM-IV (SCID; Wittchen et al., 1997). Depression was assessed with the 
German version of the Calgary Depression Rating Scale for Schizophrenia (CDSS; Müller et 
al., 1999), an observer-rated nine-item scale in which symptoms of depression are rated with 
regard to the previous week. Insight was assessed with the PANSS item G12 “insight and 
judgment” which takes awareness of symptoms, awareness of need for treatment and 
awareness of consequences of the disorder into account and is rated on a seven point Likert-
scale. The PANSS insight score has been found to be highly correlated with other established 
measures of insight (for a review of scale correlations see Lincoln et al., 2007) and is 
frequently used as global measure of insight. Delusion conviction was assessed with the 
conviction subscale of the German version of the Peters et al. Delusions Inventory (PDI; 
Lincoln et al., 2009). The PDI consists of 40 items covering a range of delusional beliefs that 
are rated in regard to presence, distress, conviction and preoccupation.  
Functioning. Occupational and social functioning were assessed with an adapted 
German version of the Role Functioning Scale (Goodman et al., 1993; Lincoln et al., 2012). 
Higher scores indicate better functioning. Social skills were assessed using the Social 
Performance Rating Scale (Fydrich & Bürgener, 1999). Scores were transformed inversely so 
that higher scores indicate more pronounced social skills.  
Neurocognition. Verbal memory was assessed with the subtest Logical Memory I of 
the Wechsler Memory Scale-Revised (WMS-R; Härting et al., 2000) and cognitive set-
shifting with the Trail Making Test, Part B (TMT; Reitan, 1992).  
Cognitive biases. The “jumping-to-conclusions-bias” (JTC) was assessed with the 
beads task (Garety et al., 2005) using a ratio of 80:20. We repeated the task three times, each 
with a different sequence of beads and counted the number of beads drawn to decide in each 
task. The score used was the mean number of draws to decision. Attribution biases were 
assessed using the ‘externalizing bias” (EB) score from the Internal, Personal and Situational 
Attributions Questionnaire (IPSAQ; Kinderman & Bentall, 1996) which is calculated by 
subtracting the number of internal attributions for negative events from the number of internal 
attributions for positive events. A higher score therefore reflects a stronger self-serving bias. 
Theory of Mind was assessed by a movie task of social situations (Mehl et al., 2010), a movie 
version of the Hinting Task (Corcoran et al., 1995). Participants watched four movie 
sequences presenting complex social situations. In the situations, a character presented a 
statement that hinted information (e.g. “My birthday is coming soon.” “This necklace is very 
beautiful.”). Participants were required to answer questions about the protagonists’ hinted 
intentions and their emotions. For this study we used the combined score of the ‘ability to 
infer intentions’ and the ‘ability to infer emotions’ (range 0-16). A detailed description of the 
task was provided in the study by Mehl et al. (2010). 
2.3.Analyses  
 Missing data. There was no missing data for PANSS scores at baseline or post-
assessment for the treatment completers, but eleven completers did not provide full data at 1-
year follow-up. We used the SPSS EM estimation to test whether missing PANSS data at 
follow-up was at random and to impute missing data (Lincoln et al., 2012). Missing data in 
the predictors was not replaced.  
The analyses were conducted in several steps. First, based on the sample of patients 
from the CBTp group who had completed therapy and the patients who had completed the 
waiting-period (n=73) we attempted to identify differential predictors of response to CBTp 
versus WL by post-assessment. We performed a series of hierarchical multiple regressions, 
with the post treatment measure (e.g. positive symptoms) as the dependent variable and the 
baseline for that variable as covariate (hence controlling for initial severity level) included in 
the first block, followed by the independent variable group (CBTp group versus WL group), 
the predictor variable (e.g. insight), and the group x predictor interaction in the second block. 
We evaluated the predictors 1 at a time. The main effect of the predictor variable indicates 
whether it predicts outcome, controlling for baseline. Main group effects reflect differences in 
primary outcomes between the two groups (treatment effects). The group x predictor 
interaction effect indicates whether the predictor predicts outcome differentially (e.g. more for 
the CBTp group than for the WL group) and is the variable of interest.  
Second, we combined the completers in the immediate (CBTp group) versus delayed 
(WL group) therapy groups (n=68) to examine predictors of change from pre-therapy to post-
therapy and one-year follow-up in a larger group of people who received CBTp. Again, we 
conducted a series of regressions in the manner described above. However, for these analyses 
the post-therapy and 1-year-follow-up assessments for all participants served as dependent 
variables and the cohort (immediate versus delayed) was the group variable. Thus, main 
effects of predictors reflect predictors of change during CBTp, controlling for baseline levels, 
across both cohorts. Main cohort effects reflect differences in primary outcomes between the 
two cohorts. Significant cohort x predictor interactions were analyzed but will not be reported 
as they were not a primary focus of the manuscript. However, detailed results and findings 
can be obtained from the authors upon request. All predictor variables that produced 
significant main effects at a probability value of p.05 were entered into regression models 
(method: ENTER) in order to assess their combined impact on outcome. 
Finally, in order to predict dropout, we used t-tests to compare completers and drop-
outs on the potential predictors used for the previous analyses (compare Table 1). We did not 
include reasoning biases or social skills in these analyses due to the lack of a rational that 
these variables would predict dropout. However, we added the number of previous 
hospitalizations as a proxy of previous experience with mental health services. Thus, we 
conducted 15 single a priori t-tests and then entered significant discriminating variables into 
logistic regression (method: ENTER) to predict their combined effect and prediction 
accuracy.  
The baseline mean values, standard deviations, ranges and possible scores for each of 
the predictors analyzed are presented in Table 1. 
 
3. Results 
3.1.Sample characteristics and therapy delivery 
Fifty-nine patients fulfilled DSM-criteria for schizophrenia, twelve for schizo-
affective disorder, five for delusional disorder and four for acute psychotic disorder. 
Comorbid Axis I disorder was diagnosed in 45 patients, comorbid Axis II disorder in 15 
patients. Sixteen percent of the sample fulfilled criteria for two or more comorbid disorders. 
Among the Axis I disorders, anxiety disorders were the most prevalent (n=25), followed by 
affective disorders (n=18) and substance abuse or dependency (n=12). Among the personality 
disorders borderline personality disorder was diagnosed the most frequently (n=4) followed 
by avoidant personality disorder (n=3).  
Eighteen patients were acutely psychotic, 56 were partly remitted and/or episodic, and 
six patients were classified as fully remitted (DSM-IV single episode, full remission). The 
mean age of the sample was 33.1 (SD=10.6) and 35 patients were female. The mean duration 
of psychosis was 10.4 years (SD=8.5). The mean number of previous episodes requiring 
hospital admission was 4.5 (SD=6.9). All but four patients were on antipsychotic medication 
and the majority was reliably taking them as prescribed (n=48). The mean GAF score was 
45.3 (SD=12.8), the mean scores for the PANSS positive, negative and general subscales were 
14.9 (SD=4.5), 14.2 (SD=4.6) and 34.0 (SD=7.5) respectively. 
Patients who completed therapy received 28.9 (SD=7.4) therapy sessions in 38.0 
(SD=15.8) weeks. The average waiting time was 19.2 weeks (SD = 7.9). The mean follow-up 
period was 53.3 weeks (SD = 40.2). Across both groups, patients received additional 7.6 
sessions (SD = 10.7) between post-therapy and one-year follow-up.  
 
3.2    Differential predictors of improvement in positive and negative symptoms by 
post-assessment between the CBTp group versus the WL group  
PANSS positive symptoms at post-assessment were significantly related to PANSS 
positive symptoms at baseline (=0.58, p0.01), as was group status (=0.28, p0.01), 
indicating the significant effect of the treatment on positive symptoms. As can be seen in 
Table 2 there were no significant interaction effects, indicating that none of the 17 variables 
investigated predicted improvement in one group more relative to the other. However, there 
were two trend effects towards significant group x predictor interactions in regard to cognitive 
set shifting and memory. Post-hoc analyses by group indicated that in the WL group impaired 
set-shifting (=0.17, p=0.14) and impaired memory performance (=-0.18, p=0.13) tended to 
predict higher levels of positive symptoms at outcome while in the CBTp group these 
variables tended to predict lower levels of positive symptoms at outcome (=-0.11, p=0.56 
and =0.18, p =0.35, respectively).  
PANSS negative symptoms at post-assessment were significantly associated with 
PANSS negative scores at baseline (=0.56, p0.01) while group status was not (=-0.06, 
p=0.58) indicating the absence of a therapy effect on negative symptoms. As can be seen in 
Table 2 only 2 of the 17 group x predictor interactions were significant. This was the case for 
duration of disorder and for JTC, with post-hoc analyses by group indicating that a longer 
duration of disorder tended to predict higher levels of negative symptoms in the CBTp 
(=0.28, p=0.07) and lower levels in the WL group (=-0.22, p=0.10) and that a stronger 
JTC-bias tended to predict negative symptoms in the WL group ( =-0.23, p=0.09) but not in 
the CBTp group (=0.20, p=0.20). Also, there was a trend interaction for comorbid Axis II 
disorders with post-hoc analyses by group indicating that comorbidity predicted more 
negative symptoms in the WL (=0.33, p0.01) but not in the CBTp group (=0.04, p=0.82).  
 
3.3.Predictors of improvement from pre-treatment to post-treatment and follow-up in the 
complete sample 
PANSS positive symptoms at post-therapy were significantly related to PANSS 
positive symptoms at baseline (=0.33, p0.01), but not to cohort (=0.15, p=0.22) indicating 
that there was no difference in outcome between the immediate (previously the CBTp group) 
and the delayed therapy group (previously the WL group). Over and beyond these variables, 
higher levels of depression (=0.40, p0.01), more negative symptoms (=0.51, p0.01), 
poorer social skills (=-0.39, p0.01), poorer role functioning (=-.48, p0.01) and poorer 
ToM ability (=-0.25, p0.05) significantly predicted positive symptoms at post-treatment. 
Together, these five variables accounted for a significant amount of variance in post-therapy 
positive symptoms over and above the variance explained by pre-therapy positive symptoms 
(change in R2=0.40, df=4,53; p0.01). PANSS positive symptoms at follow-up were not 
related to PANSS positive symptoms at baseline (=0.06, p=0.62) or to cohort (=-0.01, 
p=0.93). Over and beyond these variables, the predictors age (=0.28, p0.05), years of 
education (=0.32, p0.05), depression (=0.28, p0.05), negative symptoms (=0.31, 
p0.05) and externalizing bias (=0.36, p0.01), were significantly related to positive 
symptoms at follow-up. Together, these five variables accounted for a significant amount of 
variance in follow-up positive symptoms over and above the variance explained by pre-
therapy positive symptoms (change in R2=0.30; df=5,48; p0.01).  
PANSS negative symptoms at post-assessment were associated with PANSS negative 
symptoms at baseline ( = .32, p0.01) while cohort was not (=0.13, p=0.31). Over and 
beyond these variables, lower functioning (=-0.30, p0.05), higher delusion conviction 
(=0.46, p0.01) and more positive symptoms (=0.55, p0.01) were significantly related to 
negative symptoms at outcome. Together, these two variables accounted for a significant 
amount of variance in follow-up negative symptoms over and above the variance explained by 
pre-therapy negative symptoms (change in R2=0.33; df=3,63; p0.01). Negative symptoms at 
follow-up were associated with PANSS negative symptoms before treatment (=0.27, p0.05) 
while cohort was not (=-0.13, p=0.29). Over and beyond these variables, the predictors age 
(=0.25, p0.05) and years of education (=0.29, p0.05) were significantly related to 
negative symptoms at follow-up. Together, these two variables accounted for a significant 
amount of variance in follow-up negative symptoms over and above the variance explained by 
pre-therapy negative symptoms (change in R2=0.14; df=2,64; p0.01).  
 
3.4. Predictors of dropout 
Patients who dropped out (n=12) had been hospitalized less often (2.8, SD=1.7) than 
completers (4.8, SD=7.5; t(74.3)=2.1, p0.05), had more lack of insight (2.8, SD=1.1 vs 1.8, 
SD=1.0; t (77)=2.0, p0.01), lower social functioning (4.5, SD=3.2 vs. 7.0, SD=2.9; t(78 )=-
2.7, p0.01) and more negative symptoms (16.2, SD=2.8 vs. 14.1, SD=4.7; t(24.3)=2.1, 
p.05). They also showed a trend towards more positive symptoms (17.4, SD=5.9 vs. 13.8, 
SD=3.8; t(12.7)=1.1, p=0.06) and less Axis II disorders (O versus 15, Chi2=3.3, p=0.07). 
None of the other predictors reached significance. 
The results of logistic regression of the four significant predictors on dropout are 
presented in Table 1. As can be seen, the full model was statistically significant in predicting 
variance in dropout. However, no variable reached significance as a single predictor within 
the model. Furthermore, the baseline model already predicted dropout accurately in 85% 
based on the assumption that no patient would drop out. The regression model predicted 
seven of the dropouts correctly. However, it also incorrectly predicted three completers to be 
dropouts resulting in a total prediction accuracy of 87%. 
 
4. Discussion 
The study set out to extend on previous findings on predictors of change during CBTp 
by replicating previous findings and investigating novel predictors with specific relevance to 
CBTp. To summarize, we found that there were no significant predictors of improvement in 
positive symptoms in the CBT group compared to wait-list group and only few and weakly 
significant findings for negative symptoms. The predictor x group interactions for negative 
symptoms indicated that a longer duration of disorder predicted less improvement in negative 
symptoms in the CBTp group but not in the WL group, whereas jumping-to-conclusions was 
positively related to outcome in the WL group but not in the CBTp group. Irrespective of 
group status there were numerous predictors of change in symptoms over time. As such, we 
found depression, negative symptoms, impaired social skills, role functioning and theory of 
mind to predict 40% of positive symptom variance at post-treatment. Negative symptoms at 
post-therapy were predicted by poorer functioning, delusion conviction and more positive 
symptoms at baseline that explained 33% of the variance over and above baseline negative 
symptoms. Younger age and lower education were significantly related to more improvement 
in positive and negative symptoms at follow-up. Furthermore, improvement in positive 
symptoms at FU was predicted by lower levels of depression, negative symptoms and a less 
pronounced externalizing bias at baseline. Lack of insight and low social functioning were the 
main predictors of drop-out, contributing to a prediction accuracy of 87%.  
In regard to the variables that predict change in general, we were able to confirm a 
number of the findings from previous predictor studies. For one, we also found younger 
patients to improve more (compare Thomas et al., 2011; Morrison et al., 2012). In addition, 
we could also replicate the findings that patients with a shorter duration of disorder show 
more change during CBTp (Drury et al., 1996; Garety et al., 1997; Tarrier et al., 1998; 
Morrison et al., 2004; Allott et al., 2011; Thomas et al., 2011; Morrison et al., 2012) and were 
able to demonstrate that this predictor was specific to CBTp. Our results also corroborate the 
findings that negative symptoms at baseline are predictive of less improvement (Allott et al., 
2011; Thomas et al., 2011). However, in contrast to previous findings (Morrison et al., 2004; 
Dunn et al., 2006), we also found higher baseline-levels of positive symptoms to be predictive 
of less favorable outcome in negative symptoms. This difference in finding is likely to be 
explicable by differences in methodology and the outcome variables investigated. Finally, by 
failing to find a significant predictive effect of neurocognitive functioning, our study 
corroborates the overall pattern of findings from previous CBTp predictor research (Garety et 
al., 1997; DeVille et al., 2011; Premkumar et al., 2011) indicating that neurocognitive 
functioning is not particularly relevant to outcome. This is also in line with a review by Kurtz 
(2011) who did not find neurocognition to be predictive of change in other psychosocial 
interventions for schizophrenia. In our study, there was a tendency for participants with 
impaired memory and set-shifting abilities to have worse outcome after the WL period, but 
this effect was reversed for the CBTp group. Overall, therefore, concerns that CBT will be 
less effective for patients with poor neurocognitive functioning seem to be unfounded. 
Other findings were not directly in line with previous ones: Our study was the first to 
identify depression as a negative predictor of improvement in positive symptoms. However, 
this finding fits in well with the accumulating evidence which indicates that depression and 
affective processes play a major role in maintaining and predicting positive symptoms (Myin-
Germeys & van Os, 2007; Fowler et al., 2012; Freeman, Dunn, et al., 2012; Freeman, Stahl, et 
al., 2012). In contrast to previous work (Drury et al., 1996; Brabban et al., 2009) we did not 
find women to improve more. Also, other than Allott et al. (2011) we found lower rather than 
higher education to predict long-term improvement, which might, however, be due to the fact 
that Allott et al. focused on functioning at the end of therapy rather than on change. 
Surprisingly, we did not find that higher insight or lower delusion conviction predict better 
outcome (compare Garety et al., 1997; Brabban et al., 2009). This divergence could be 
interpreted as promising in the sense that the working with delusions approach worked 
sufficiently well for patients with little insight. On the other hand, patients with less insight 
were more likely to drop out. Also, several relevant aspects of insight, such as need for 
treatment and recognition of presence of a mental illness were probably generally high as the 
patients were attending the outpatient treatment on their own free will, presumably out of a 
felt need for treatment. Possibly, a more detailed assessment of insight that differentiates 
between insight into need for treatment and insight into the nature of symptoms would have 
produced different findings. Also, a measure that assesses delusion conviction related to the 
individuals’ specific delusional beliefs as used in the study by Garety et al. (1997) might have 
been more conclusive than the conviction subscale of the PDI. 
With regard to our novel predictors, we found that a stronger JTC-bias tended to 
predict more negative symptoms after the waiting period but less negative symptoms after 
CBTp. The direction of this effect was surprising, perhaps, as we had expected patients with 
lower reasoning biases to benefit more, based on the resource assumption put forward by 
Grawe (2002). Our finding is in line with the more classic assumption that the success of 
therapy is attributable to correcting reasoning biases. In contrast though, more impairment in 
ToM and a stronger self-serving attribution bias were related to higher levels of positive 
symptoms at outcome. As these findings were based on the combined treatment sample they 
are not necessarily specific to CBTp and warrant replication using a more rigorous design. 
The findings on comorbidity were more straightforward: Although the hypothesis that 
patients with comorbid Axis I disorders would benefit more was not supported, the expected 
detrimental effect of comorbid II disorders that has been found in regard to the treatment of 
other Axis I disorders (Reich, 2003) was also absent. The trend towards an interaction effect 
indicated that - if present at all - the negative predictive value of comorbid Axis II disorders 
was restricted to the WL group.  
Finally, we found that patients who dropped out during the assessment phase or 
therapy had been hospitalized less frequently, showed less insight and had lower social 
functioning and more negative symptoms. This pattern of findings indicates that there might 
be a more socially isolated and difficult-to-reach subgroup of highly symptomatic patients 
with low insight, who are more sceptical of services and treatment offers. However, the 
combination of these variables could hardly improve the overall prediction of drop-out, which 
is partly explicable by the small numbers of dropout. 
We would like to note some methodological aspects that affect the comparability of 
our findings to previous studies. Overall, despite the absence of exclusion criteria, the sample 
in our study was comparable to samples from previous CBTp treatment trials in terms of their 
baseline PANSS scores (e.g. Rector et al., 2003; Bechdolf et al., 2004; Valmaggia et al., 
2005), age, gender and length of disorder (Lincoln et al., 2008). Also, the drop-out rates and 
pre-post effect sizes for positive symptoms were in the range of those found in the literature 
(Lincoln et al., 2008). Nevertheless, fewer patients benefited in terms of negative symptoms 
and this might have led to an underestimation of predictors for negative symptom 
improvement.   
A limitation of this study is the fairly small number of patients on which the CBTp 
versus WL comparisons are based (34 versus 39). Also, the lack of a control condition for the 
follow-up analyses makes it impossible to conclude whether variance in follow-up change is 
related to CBTp. Furthermore, the combined groups differed in the number of assessments 
and the overall time they spent in the treatment project. We controlled for possible cohort 
effects by including predictor x cohort interactions in the analyses based on the combined 
sample. However, there were few significant interactions and these were not straightforward 
to interpret. Finally, in the light of the numerous single regression analyses that were not 
adjusted to reduce type I error, the single findings must be interpreted with caution. This 
applies especially to the few significant specific predictors of change in the CBTp versus 
wait-list group and to the individual significant predictors in drop-out analyses, of which none 
reached significance in the logistic regression. 
A strength of our study is that the analyses were based on a clinically heterogeneous 
sample of unselected patients. This might explain why we were able to identify a larger 
number of predictors than many of the previous studies that were largely based on more 
selective samples of patients who were more homogenous in terms of symptom severity, 
comorbidity and functioning.  
 Although we were able to identify numerous predictors of change in the combined 
sample, the analyses of CBTp specific predictors based on the controlled design do not 
provide a sufficient basis to pre-select patients that should or should not be referred to CBTp. 
Despite the inclusion of numerous potential predictors there was a marked absence of patient 
characteristics that significantly predicted whether a patient will improve during CBTp or not. 
The only noteworthy significant CBTp specific predictor of improvement in negative 
symptoms was a shorter duration of disorder. On the background of the other studies with 
similar findings, this indicates that it is important to get patients into treatment at an earlier 
stage. On a more positive note, the findings indicate that lower education, neurocognitive 
deficits and comorbid disorders pose no barrier to improvement during CBT. Based on the 
findings of the predictors of symptom change that took place irrespective of group status, one 
could speculate that the effect of CBTp might be further enhanced by including a more 
thorough baseline assessment of comorbid depression, reasoning biases and social cognition 
and targeting these domains in a more profound way. Possibly the use of more behavioral 
activation techniques, placing a stronger emphasis on improving self-esteem and using 
interventions aimed at emotion regulation might prove helpful for patients with comorbid 
depression. Also, we need to undertake more effort to understand why patients with poor 
social functioning, lack of insight and negative symptoms discontinue therapy, and reflect on 
how drop-out in this group might be prevented, for example by doing home visits or adapting 
the setting (e.g. going for walks with the patient).  
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Table 1 Overview of the means and ranges of the potential predictors of outcome at baseline  
 
CBTp first sample (N = 
34) 
WL / delayed CBT sample 
(N =39)  
 M / % SD range M / % SD range 
Possible 
Range 
Socio-demographic variables 
Female gender 
47.06 
% - - 
43.59 
% - - - 
Age 33.44 10.06
19 - 
52 33.44 10.85 17 - 63 - 
Years of education 15.07 4.14 3 - 24 15.77 3.42 10 - 23 - 
Clinical variables 
Duration of disorder 
(in years) 11.26 10.15 1 - 35 9.76 6.92 0.5 - 32 - 
Number of 
hospitalizations a 5.56 8.69 0 - 35 3.90 5.65 0 - 25 - 
Comorbid Axis I 
disorder 
53.94 
% - - 
49.83 
% - - - 
Comorbid Axis II 
disorder  
26.47 
% - - 
15.38 
%  - - - 
Symptom severity 
Positive symptoms 
(PANSS) 14.38 3.58 9 - 24 14.69 4.65 7 - 27 7 - 49 
Negative symptoms 
(PANSS) 14.59 4.86 9 - 26 13.28 4.52 7 - 24 7 - 49 
Delusion conviction 
(PDI) 29.88 26.64
0 - 
103 24.64 23.49 0 - 109 0 - 200 
Lack of Insight 
(PANSS G-12) 1.94 1.13 1 - 5 1.87 0.95 1 - 4 1 - 7 
Depression (CDSS) 7.15 4.32 1 - 13 5.54 3.22 1 - 13   0 - 27 
Social functioning 
Role Functioning Scale 27.35 10.24 2 - 44 30.26 6.73 16 - 43   0 - 48 
Social skills 19.29 3.87 7 - 25 20 4.61 7 - 27 5 - 30 
Neurocognitive variables 
Cognitive flexibility 
(TMT-B) b 70.26 33.06
19 - 
151 56.63 20.22 27 - 96  
Memory (WMS) 23.5 8.33 6 - 41 26.97 8.89 12 - 41  
Reasoning biases 
Jumping-to-
conclusions c 12.21 4.48 4 - 26 15.69 5.47 3 - 28 3 - 30 
Internal attributions of 
neg. events 7.79 3.62 2 - 13 7.94 3.48 0 - 16 0 - 20 
Theory of mind 9.57 3.05 3 - 15 9.95 2.27 4 - 14 0 - 16 
 Note.PANSS = Positive and Negative Syndrome Scale; PDI = 
Peters et al. Delusion Inventory; CDSS = Calgary Depression 
Rating Scale for Schizophrenia; WAIS-Inf = Wechsler Adult 
Intelligence Scale – Information subscale; TMT = Trail-Making 
Test; WMS = Wechsler Memory Scale 
a = variable used for prediction of dropout only 
b = higher scores reflect higher completion times 
c = higher scores reflect a larger number of beads drawn, therefore a 
lower tendency to jump-to-conclusions  
Table 2 Linear Regressions of the Group x Predictor Interaction on Positive and Negative Symptoms 
Controlling for Baseline Symptoms 
 Negative Symptoms Positive Symptoms 
Predictor   p  p 
Socio-demographic variables     
Female gender 0.017 0.856 -0.132 .187 
Age 0.118 0.906 0.049 .629 
Years of education -0.011 0.901 0.131 .194 
Clinical variables     
Duration of disorder 0.050 0.614 0.251 0.015 
Comorbid Axis I disorder 0.010 0.914 0.002 0.981 
Comorbid Axis II disorder  0.043 0.654 -0.192 0.052 
Symptom severity     
Negative/positive symptoms (PANSS)a -0.093 0.289 0.019 0.859 
Delusion conviction (PDI) 0.019 0.845 0.072 0.481 
Lack of Insight (PANSS G-12) -0.093 0.326 -0.161 0.108 
Depression (CDSS) 0.057 0.554 -0.129 0.176 
Social functioning     
Role Functioning Scale 0.069 0.469 0.002 0.988 
Social skills  -0.063 0.523 -0.023 0.821 
Neurocognitive variables     
  Cognitive flexibility (TMT-B) -0.184 0.075 0.101 0.363 
  Memory (WMS) 0.187 0.061 -0.129 0.191 
Reasoning biases     
  Jumping-to-conclusions -0.054 0.580 0.217 0.039 
  Internal attributions of neg. events 0.036 0.731 -0.186 0.110 
  Theory of mind 0.088 0.341 0.087 0.375 
Note. Baseline symptoms were entered in block one (with  = 0.59, p< 0.001 for positive symptoms 
and  = 0.56, p < 0.001 for negative symptoms). Group status was entered in block two along with 
the predictor and the group x predictor interaction (with s ranging from 0.27-.36, all ps<0.01, for 
positive symptoms and from -0.04 - -0.12, all ps>0.20 for negative symptoms). 
a Baseline negative symptoms were entered as a predictor of positive symptoms at outcome and 
baseline positive symptoms were entered as a predictor of negative symptoms at outcome
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Table 3 Results of the logistic regression of predictors on dropout versus non-dropout  
  95% CI for Odds Ratio  
Included B(SE) Lower Odds Ratio Upper 
Constant -.68 (2.1)    
No of previous hospitalisations -.09 (.09) .78 .92 1.1 
Negative symptoms -.04 (.10) .79 .96 1.2 
Insight .57 (.32) .96 1.8 3.4 
Social functioning -.38 (.16) .66 .78 1.0 
Note. R2=.14 (Cox & Snell), .25 (Nagelkerke). Model 2(4)=12.2, p=.016.  

Figure 1 - Timepoints of the Assessments in the CBTp and the Waitlist Group. 
